Published in
American Society of Hematology, Blood, 2(131), p. 226-235, 2018
DOI: 10.1182/blood-2017-08-799080
Links
Tools
FOXP1 expression is a prognostic biomarker in follicular lymphoma treated with rituximab and chemotherapy
Journal article published in 2017 by
Anja Mottok 
,
Vindi Jurinovic,
Pedro Farinha ,
Andreas Rosenwald,
Ellen Leich ,
German Ott ,
Heike Horn,
Wolfram Klapper,
Michael Boesl,
Wolfgang Hiddemann,
Christian Steidl ,
Joseph M. Connors ,
Laurie H. Sehn,
Randy D. Gascoyne ,
Eva Hoster
and other authors.
,
Vindi Jurinovic,
Pedro Farinha ,
Andreas Rosenwald,
Ellen Leich ,
German Ott ,
Heike Horn,
Wolfram Klapper,
Michael Boesl,
Wolfgang Hiddemann,
Christian Steidl ,
Joseph M. Connors ,
Laurie H. Sehn,
Randy D. Gascoyne ,
Eva Hoster
and other authors.
Distributing this paper is prohibited by the publisher
Full text: Unavailable
Preprint: archiving forbidden
Published version:
archiving forbidden
Data provided by 
Abstract
Key PointsHigh expression of FOXP1 predicts adverse FFS in patients with FL treated with immunochemotherapy. FOXP1 high and low expressors differ in specific gene mutations and gene expression changes.